Install
PR Newswire’s news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.
- 5,878articles · 30d
- 2+ hour agolatest article
- Aug 14, 2026earliest in window
- 92%with images
- 272avg words
- Economy, Business & Finance 2,758
- Finance & Business 2,211
- News 1,475
- Business & Industrial 778
- Science & Technology 646
- Health & Wellness 598
- Medical 555
- Arts, Culture, Entertainment & Media 514
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
iFlex Stretch Studios Adds Kinotek® 3D Movement Technology to Every Experience
3+ day, 21+ hour ago (256+ words) Sep 09, 2026, 19:11 ET Before a therapist begins a session, Kinotek's markerless 3D movement assessment captures a client's body in motion – no markers, sensors, or wearables required. In seconds, the technology analyzes range of motion, symmetry, and movement quality to provide deeper insights…...
SONEX HEALTH ANNOUNCES PUBLICATION OF LARGEST OFFICE-BASED ULTRASOUND-GUIDED CARPAL TUNNEL RELEASE STUDY WITH TWO-YEAR FOLLOW-UP
1+ week, 4+ day ago (101+ words) Sep 02, 2026, 10:00 ET Data confirms office-based UGCTR as safe and effective option with patient-centered benefits of rapid improvement, fast return to activities and work, and durable improvements through two years without recurrences Key takeaways from patients treated with an office-based UGCTR…...
PleoPharma Awarded $6.5 Million NIDA Grant to Support Phase 3 Trial of PP-01 for Cannabis Withdrawal in Patients with Cannabis Use Disorder
3+ week, 3+ day ago (143+ words) Aug 20, 2026, 08:04 ET NIH/NIDA funding will support a pivotal clinical program for an investigational treatment for adults with cannabis use disorder These successful results have paved the way for CAN-004, the ongoing pivotal Phase 3 trial, with the first patient dosed…...